Cyclopharm Targets Up to 300 US Technegas® Installations by Late 2026

Expanding Footprint Across Diverse US Healthcare Segments

Cyclopharm Limited (ASX: CYC) has announced a significant acceleration in the rollout of its Technegas® lung ventilation imaging technology across the United States. The company’s latest update highlights new contracts and installations spanning four strategically important regions, including federal research institutions, regional health systems, and large metropolitan independent delivery networks (IDNs).

At the forefront is a purchase order from the National Institutes of Health (NIH) in the Mid-Atlantic region, marking a notable expansion into federal healthcare and research environments. This complements Cyclopharm’s existing footprint within Veterans Administration and military hospitals, underscoring growing institutional validation of Technegas® in government settings.

Regional Growth and Strategic Network Penetration

Cyclopharm’s first clinical entry into the Pacific Northwest has been established through installations at two sites within the St. Charles Health System in Oregon. This regional not-for-profit network serves Central and Eastern Oregon, providing a new corridor for clinical adoption and a platform for further expansion into adjacent IDNs.

Meanwhile, in Central Florida, Cyclopharm has secured a two-site commercial agreement with UF Health, building on existing installations within other major IDNs in the region. This cluster-based expansion reflects the company’s strategy to leverage regional density, where proven clinical outcomes and operational familiarity accelerate multi-site adoption within affiliated networks.

Major Metropolitan Engagement and Commercial Model

In North Texas, Cyclopharm has inked a contract with Texas Health Presbyterian Hospital Dallas, part of Texas Health Resources, one of the largest non-profit health systems serving the Dallas–Fort Worth metro area. This deal exemplifies the company’s focus on large metropolitan IDNs capable of driving system-wide adoption following initial implementations.

Each Technegas® installation generates recurring revenue through per-patient ventilation imaging procedures, with consumables and service contracts providing ongoing income streams. As installations multiply, Cyclopharm anticipates enhanced revenue visibility and operational leverage, supported by a diversified base spanning federal, regional, and metropolitan healthcare providers.

Outlook and Strategic Momentum

CEO James McBrayer emphasised the momentum behind Cyclopharm’s US commercial strategy, noting the company currently operates 46 revenue-generating locations with near-term installations underway. The goal is to reach between 250 and 300 installations by the second half of 2026, a target that, if achieved, would represent a substantial scaling of the company’s US presence.

This growth is underpinned by a phased rollout approach: establishing foundational clinical validation, building regional density to strengthen contracting leverage, and ultimately pursuing system-wide expansion. Dedicated business development efforts and improving reimbursement clarity are accelerating contracting cycles and multi-site agreement conversions.